Immutep Limited (NASDAQ:IMMP) recently secured a deal with Indian firm Dr. Reddy’s Laboratories Ltd. to develop and commercialize their Eftilagimod Alfa cancer drug outside specific regions. The agreement includes a $20 million upfront payment for Immutep. Positive results from phase one and phase two studies of the drug showed efficacy in treating soft tissue sarcoma and metastatic non-squamous non-small cell lung cancer. While IMMP shows investment potential, some AI stocks may offer higher returns with less risk. The deal with Dr. Reddy’s is a significant win for Immutep in the biotechnology sector.

Read more at Yahoo Finance: Immutep (IMMP) Scores Win After Announcing Deal With Indian Firm